PE20011177A1 - 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE - Google Patents

5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE

Info

Publication number
PE20011177A1
PE20011177A1 PE2001000216A PE2001000216A PE20011177A1 PE 20011177 A1 PE20011177 A1 PE 20011177A1 PE 2001000216 A PE2001000216 A PE 2001000216A PE 2001000216 A PE2001000216 A PE 2001000216A PE 20011177 A1 PE20011177 A1 PE 20011177A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrimidines
methyl
alkylpyride
cycline
Prior art date
Application number
PE2001000216A
Other languages
Spanish (es)
Inventor
Richard John Booth
Scott Norman Vanderwel
Peter Laurence Toogood
Ellen Myra Dobrusin
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20011177A1 publication Critical patent/PE20011177A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A DERIVADOS DE 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS DE FORMULA I DONDE R2 ES H, ALQUILO, CARBOCICLICO C3-C7; R3 ES H, ALQUILO, ALCOXI, HALOGENO, TRIFLUOROMETILO, ALQUINILO, ALQUENILO, ENTRE OTROS; Y ES N, CR7; R9 ES ALQUILO, HALOALQUILO, ARILO; X Y Z SON H, HALOGENO, ALQUILO, ALCOXI, TRIFLUOROMETILO, HIDROXI, NITRILO, NR4R5, ENTRE OTROS; R4 Y R5 SON H, ALQUILO, ALQUENILO, ALQUINILO, (CH2)nAr, ARILALQUILO, ARILO, HETEROARILO, HETEROARILALQUILO, ENTRE OTROS; R7 ES NR4R5, N(O)R4R5, OH, OR4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 8-CICLOPENTIL-5-METIL-2-(4-PIPERAZIN-1-IL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA,8-(1-METILETIL)-5-METIL-2-(4-PIPERAZIN-1-IL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA,8-CICLOPENTIL-5-METIL-2-(4-FLUORO-3-METIL-FENILAMINO)-8H-PIRIDO[2,3]PIRIMIDIN-7-ONA, ENTRE OTROS. LOS COMPUESTOS DE 5-ALQUILPIRIDO [2,3-d] PIRIMIDINAS SON INHIBIDORES DE TIROSINA CINASAS DEPENDIENTES DE CICLINA (Cdk) Y SON UTILES PARA EL TRATAMIENTO DE INFLAMACION, ENFERMEDADES PROLIFERATIVAS, CANCER, RESTENOSIS, ENFERMEDADES NEURODEGENERATIVASREFERS TO DERIVATIVES OF 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES OF FORMULA I WHERE R2 IS H, ALKYL, CARBOCYCLIC C3-C7; R3 IS H, ALKYL, ALCOXY, HALOGEN, TRIFLUOROMETHYL, ALKINYL, ALKENYL, AMONG OTHERS; Y IS N, CR7; R9 IS ALKYL, HALOALKYL, ARYL; X AND Z ARE H, HALOGEN, ALKYL, ALCOXY, TRIFLUOROMETHYL, HYDROXY, NITRILE, NR4R5, AMONG OTHERS; R4 AND R5 ARE H, ALKYL, ALKENYL, ALKINYL, (CH2) nAr, ARYLALKYL, ARYL, HETEROARYL, HETEROARYALKYL, AMONG OTHERS; R7 IS NR4R5, N (O) R4R5, OH, OR4, AMONG OTHERS. PREFERRED COMPOUNDS ARE 8-CYCLOPENTIL-5-METHYL-2- (4-PIPERAZIN-1-IL-PHENYLAMINE) -8H-PYRIDO [2,3] PYRIMIDIN-7-ONA, 8- (1-METHYLETHYL) -5-METHYL -2- (4-PIPERAZIN-1-IL-PHENYLAMINE) -8H-PYRIDO [2,3] PYRIMIDIN-7-ONA, 8-CYCLOPENTIL-5-METHYL-2- (4-FLUORO-3-METHYL-PHENYLAMINE) -8H-PIRIDO [2,3] PYRIMIDIN-7-ONA, AMONG OTHERS. THE COMPOUNDS OF 5-ALKYLPYRIDO [2,3-d] PYRIMIDINES ARE INHIBITORS OF CYCLINE-DEPENDENT TYROSINE KINASES (Cdk) AND ARE USEFUL FOR THE TREATMENT OF INFLAMMATION, PROLIFERATIVE DISEASES, CANCER, RESTENADESIS, ILLNESS

PE2001000216A 2000-03-06 2001-03-05 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE PE20011177A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
PE20011177A1 true PE20011177A1 (en) 2001-11-23

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000216A PE20011177A1 (en) 2000-03-06 2001-03-05 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE

Country Status (36)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
IL155367A0 (en) 2000-10-23 2003-12-23 Smithkline Beecham Corp NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES
CA2434834C (en) * 2001-02-12 2010-09-14 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
MXPA03007623A (en) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Pyridopyrimidine or naphthyridine derivative.
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
DK1470124T3 (en) * 2002-01-22 2006-04-18 Warner Lambert Co 2- (Pyridin-2-yl amino) pyrido [2,3] pyrimidin-7-one
EP1499320B1 (en) 2002-04-19 2007-08-22 Smithkline Beecham Corporation Novel compounds
DE60313339T2 (en) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. PROTEIN TYROSINE KINASE INHIBITORS
CA2542007C (en) 2002-10-09 2010-06-29 Wayne R. Danter Protein tyrosine kinase inhibitors
DE602004021558D1 (en) * 2003-01-17 2009-07-30 Warner Lambert Co 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
AU2004268621C1 (en) * 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
EP1685131B1 (en) 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
JP2008510770A (en) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel pteridinone as a PLK inhibitor
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
WO2006110298A2 (en) 2005-03-25 2006-10-19 Glaxo Group Limited 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
PE20100741A1 (en) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPOUNDS DERIVED FROM 3,4-DIHYDROPYRIMIDE [4,5-d] PYRIMIDIN-2 (1H) -ONE AS KINASE INHIBITORS p38
PE20061351A1 (en) 2005-03-25 2007-01-14 Glaxo Group Ltd 8H-PYRID [2,3-d] PYRIMIDIN-7-ONA 2,4,8-TRISUSTITUTED COMPOUNDS AS CSBP / RK / p38 KINASE INHIBITORS
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
EP1931670B1 (en) 2005-10-07 2012-09-12 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k
KR101492795B1 (en) * 2005-10-07 2015-02-13 엑셀리시스, 인코포레이티드 PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
MY146420A (en) 2006-09-15 2012-08-15 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
BRPI0715566A2 (en) * 2006-10-16 2013-07-02 Gpc Biotech Inc compound, prodrug, pharmaceutical composition, use of a compound, method for inhibiting cell proliferation and method for synthesizing a compound
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
US8138181B2 (en) * 2007-04-03 2012-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
PL2168966T3 (en) * 2007-06-15 2017-06-30 Msd K.K. Bicycloaniline derivative
US8329695B2 (en) 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
WO2009126584A1 (en) * 2008-04-07 2009-10-15 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2350070A1 (en) 2008-09-30 2011-08-03 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k and mtor
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2011044535A2 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011075616A1 (en) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
DK2600719T3 (en) * 2010-08-05 2014-12-15 Univ Temple 2-Substituted 8-alkyl-7-oxo-7,8-dihydropyrido [2,3-d] pyrimidine-6-carbon nitriles and uses thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
KR20160035613A (en) 2011-03-23 2016-03-31 암젠 인크 Fused tricyclic dual inhibitors of cdk 4/6 and flt3
ES2604191T3 (en) * 2011-05-17 2017-03-03 Principia Biopharma Inc. Tyrosine Kinase Inhibitors
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
CA2864142A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
MX363715B (en) * 2013-02-21 2019-03-29 Pfizer Solid forms of a selective cdk4/6 inhibitor.
EP3024464A1 (en) 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Treatment of myelodysplastic syndrome
EP3172214B1 (en) * 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
UA124804C2 (en) 2016-08-15 2021-11-24 Пфайзер Інк. Pyridopyrimdinone cdk2/4/6 inhibitors
JP7226804B2 (en) * 2017-03-03 2023-02-21 オークランド ユニサービシズ リミテッド FGFR kinase inhibitor and pharmaceutical use
MA51846A (en) 2018-02-15 2021-04-21 Nuvation Bio Inc HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS
TW202035406A (en) * 2018-12-07 2020-10-01 大陸商杭州英創醫藥科技有限公司 Heterocyclic compound as CDK-HDAC dual pathway inhibitor
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
CN114901659A (en) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 Fused pyrimidinone compounds as JAK inhibitors
WO2022188755A1 (en) * 2021-03-08 2022-09-15 暨南大学 Pyridopyrimidine-based compound and application thereof
WO2024056091A1 (en) * 2022-09-16 2024-03-21 华东师范大学 Pyridonopyrimidine derivative as rsk inhibitor and use thereof
WO2024099403A1 (en) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EP0964864B1 (en) * 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
PL344248A1 (en) * 1998-05-26 2001-10-22 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Also Published As

Publication number Publication date
TNSN01036A1 (en) 2005-11-10
SV2001000338A (en) 2001-11-30
MXPA02008535A (en) 2002-12-13
CO5280200A1 (en) 2003-05-30
IS6524A (en) 2002-08-23
AU2001233028A1 (en) 2001-10-03
AR034119A1 (en) 2004-02-04
NO20024235D0 (en) 2002-09-05
PL358271A1 (en) 2004-08-09
HN2001000040A (en) 2001-09-06
HUP0300136A2 (en) 2003-05-28
YU66502A (en) 2005-09-19
MA26881A1 (en) 2004-12-20
OA12227A (en) 2004-03-18
NO20024235L (en) 2002-11-05
DZ3308A1 (en) 2001-09-27
CA2401368A1 (en) 2001-09-27
SK12472002A3 (en) 2003-04-01
ZA200207110B (en) 2003-12-04
BG107161A (en) 2003-06-30
WO2001070741A1 (en) 2001-09-27
KR20020075805A (en) 2002-10-05
EE200200506A (en) 2004-02-16
EA200200802A1 (en) 2003-02-27
EP1268476A1 (en) 2003-01-02
AP2002002643A0 (en) 2002-12-31
HRP20020798A2 (en) 2004-02-29
PA8513201A1 (en) 2003-06-30
IL151480A0 (en) 2003-04-10
BR0109056A (en) 2003-06-03
JP2003528101A (en) 2003-09-24
CZ20022929A3 (en) 2003-02-12
GT200100037A (en) 2002-03-04
CR6736A (en) 2004-03-10
NZ520962A (en) 2003-09-26
CN1422268A (en) 2003-06-04

Similar Documents

Publication Publication Date Title
PE20011177A1 (en) 5-ALKYLPYRIDE [2,3-d] PYRIMIDINES ARE INHIBITORS OF TYROSINE KINASES AND DEPENDING ON CYCLINE
EA200500721A1 (en) Pyrimidines inhibiting CHK, PDK and ACT, THEIR RECEIVING AND USING AS MEDICINES
PE20030975A1 (en) 2- (PYRIDIN-2-ILAMINO) -PYRIDO [2,3-d] PYRIMIDIN-7-ONAS
PE20021096A1 (en) DERIVATIVES OF 4-AMINO-5-PHENYL-7-CYCLOBUTYL-PIRROLO [2,3-D] PYRIMIDINE AS INHIBITORS OF IGF-IR TYROSINE-KINASE
PE20021010A1 (en) SPIROCYCLIC DERIVATIVES AS PHOSPHODIESTERASE-7 INHIBITORS
UY27714A1 (en) 2 - HETEROARIL - CDK INHIBITING PYRIMIDINES, ITS PREPARATION AND ITS USE AS MEDICATIONS.
MXPA02011426A (en) bgr; CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE.
ECSP024399A (en) BENZOTIAZOL DERIVATIVES
ES2195785B1 (en) NEW DERIVATIVES OF PIRIDAZIN-3 (2H) -ONA.
PA8609201A1 (en) REPLACED PYRIDINONES
UY27604A1 (en) CHEMICAL COMPOUNDS.
HN2002000067A (en) INHIBITORS OF THE RHO - QUINASA.
PE20060504A1 (en) PYRIMIDINE DERIVATIVES IN THE TREATMENT OF CANCER
BR0206633A (en) 1-Aryl- or 1-Arylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
CU23148A3 (en) AZAPOLICICLIC COMPOUNDS CONDENSED WITH ARILO
UY27234A1 (en) NOVELTY INHIBITORS OF TYROSINE KINASE
PA8432901A1 (en) PIRIDILPIRROL COMPOUNDS
PE20030735A1 (en) BENZOTHIAZOLE DERIVATIVES
PE20030739A1 (en) ADENOSINE A2A RECEPTOR ANTAGONISTS
SV2003001173A (en) 1-RENT OR 1-CICLOALQUIL-TRIAZOLO [4,3-A] QUINAZOLIN-5- WAVES AS PHOSPHODIESTERASE INHIBITORS
AR053554A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
BR0215151A (en) Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
CO5170529A1 (en) DERIVATIVES OF 5- (REPLACED PHENYL) -2-PIPERAZINIL-PIRIMIDIN- (3,5- BISTRIFLUORO-METIL-BENCIL) -METIL-AMIDA
MX2009008386A (en) 2-amin0-5, 7-dihydr0-6h- pyrrolo [3, 4-d] pyrimidine derivatives as hsp-90 inhibitors for treating cancer.
ATE346067T1 (en) CARBOLINE DERIVATIVES

Legal Events

Date Code Title Description
FC Refusal